Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Prelude Therapeutics Inc shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Prelude Therapeutics Inc shareholders approved Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-16 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Prelude Therapeutics Inc shareholders approved Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier at the 2023-06-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-16
Exact text from the filing
Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal.
View on SEC.gov